REG - ReNeuron Group plc - Exercise of options, PDMR dealing and TVR

ReNeuronAnnouncement

09/05/2019 17:10

RNS Number : 5752Y
ReNeuron Group plc
09 May 2019
 


 
 



9 May 2019


AIM: RENE



 
ReNeuron Group plc
 
Exercise of options, PDMR dealing and
total voting rights
 
ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that it has received notices to exercise options from certain PDMRs of the Company to subscribe for a total of 65,792 new ordinary shares of 1 pence each in the Company ("Ordinary Shares").
 
On 9 May 2019, Sharon Grimster, VP Development and General Manager Wales, exercised options over 39,960 Ordinary Shares at an exercise price of 100 pence per share. Subsequently, on 9 May 2019, Mrs Grimster sold 39,960 Ordinary Shares at a share price of 267 pence.
 
On 9 May 2019, Dr Randolph Corteling, Head of Research, exercised options over 25,832 Ordinary Shares at an exercise price of 100 pence per share. Subsequently, on 9 May 2019, Dr Corteling sold 25,832 Ordinary Shares at a share price of 267 pence.
 
Total voting rights
Following the issue of 65,792 Ordinary Shares pursuant to the exercise of options described above, together with exercise of options by other staff under its existing blocklisting arrangements, the Company has 31,799,617 ordinary shares of 1 pence each in issue, all with voting rights. The Company holds no ordinary shares in treasury. The above figure of 31,799,617 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.
  
 
ENDS
ENQUIRIES:
 



ReNeuron


+44 (0)20 3819 8400




Olav Hellebø, Chief Executive Officer








Michael Hunt, Chief Financial Officer
 








 
Buchanan


+44 (0) 20 7466 5000




Mark Court, Sophie Wills, Tilly Abraham
 




























Stifel Nicolaus Europe Limited


+44 (0) 20 7710 7600




Jonathan Senior, Stewart Wallace, Ben Maddison








(NOMAD and Joint Broker)
 








N+1 Singer


+44 (0) 20 7496 3000




Aubrey Powell, Mark Taylor (Joint Broker)







 
 
 
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation and provide further detail.
 
 



1 


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Sharon Grimster




2


Reason for the notification 




a)


Position/status 


VP Development and General Manager Wales




b)


Initial notification /Amendment 


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


ReNeuron Group plc




b)


LEI  


2138003TU12CQ5TZO137




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument 
Identification code 


Ordinary Shares of 1 pence each
 
RENE - GB00BF5G6K95




b)


Nature of the transaction 


Exercise of options over ordinary shares




c)


Price(s) and volume(s)
 





 Price(s) 


Volume(s)




100 pence


39,960



 




d)
 


Aggregated information 
 


N/A




e)


Date of the transaction 


09 May 2019




f)


Place of the transaction 


London Stock Exchange, AIM Market



 
 
 



1 


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Sharon Grimster




2


Reason for the notification 




a)


Position/status 


VP Development and General Manager Wales




b)


Initial notification /Amendment 


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


ReNeuron Group plc




b)


LEI  


2138003TU12CQ5TZO137




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument 
Identification code 


Ordinary Shares of 1 pence each
 
RENE - GB00BF5G6K95




b)


Nature of the transaction 


Sale of ordinary shares




c)


Price(s) and volume(s)
 





 Price(s) 


Volume(s)




267 pence


39,960



 




d)
 


Aggregated information 
 


N/A




e)


Date of the transaction 


09 May  2019




f)


Place of the transaction 


London Stock Exchange, AIM Market



 
 



1 


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Randolph Corteling




2


Reason for the notification 




a)


Position/status 


Head of Research




b)


Initial notification /Amendment 


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


ReNeuron Group plc




b)


LEI  


2138003TU12CQ5TZO137




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument 
Identification code 


Ordinary Shares of 1 pence each
 
RENE - GB00BF5G6K95




b)


Nature of the transaction 


Exercise of options over ordinary shares




c)


Price(s) and volume(s)
 





 Price(s) 


Volume(s)




100 pence


25,832



 




d)
 


Aggregated information 
 


N/A




e)


Date of the transaction 


09 May 2019




f)


Place of the transaction 


London Stock Exchange, AIM Market



 
 



1 


Details of the person discharging managerial responsibilities / person closely associated




a)


Name


Randolph Corteling




2


Reason for the notification 




a)


Position/status 


Head of Research




b)


Initial notification /Amendment 


Initial notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


ReNeuron Group plc




b)


LEI  


2138003TU12CQ5TZO137




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument 
Identification code 


Ordinary Shares of 1 pence each
 
RENE - GB00BF5G6K95




b)


Nature of the transaction 


Sale of ordinary shares




c)


Price(s) and volume(s)
 





 Price(s) 


Volume(s)




267 pence


25,832



 




d)
 


Aggregated information 
 


N/A




e)


Date of the transaction 


09 May  2019




f)


Place of the transaction 


London Stock Exchange, AIM Market



 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAKSNEEANEFF